Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.78 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.66 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8594085 | 1.00 | MAP3K5 (0.78) | MAP3K5PTPN22APEX1MAPTHIF1AN | |
| SCHEMBL8594082 | 1.00 | MAP3K5 (0.78) | MAP3K5PTPN22APEX1MAPTHIF1AN | |
| SCHEMBL3893480 | 0.90 | PTPN22 (0.72) | MAP3K5PTPN22APEX1MAPTHIF1AN | |
| SCHEMBL16492645 | 0.90 | PTPN22 (0.75) | MAP3K5PTPN22APEX1MAPTHIF1AN | |
| SCHEMBL3893475 | 0.90 | PTPN22 (0.72) | MAP3K5PTPN22APEX1MAPTHIF1AN | |
| SCHEMBL13056366 | 0.90 | MAPT (0.79) | MAP3K5PTPN22APEX1MAPTHIF1AN | |
| SCHEMBL3901648 | 0.90 | MAP3K5 (0.89) | MAP3K5PTPN22MAPTHIF1ANSTAT3 | |
| SCHEMBL8593141 | 0.90 | MAP3K5 (0.89) | MAP3K5PTPN22MAPTHIF1ANSTAT3 | |
| SCHEMBL3901649 | 0.90 | MAP3K5 (0.89) | MAP3K5PTPN22MAPTHIF1ANSTAT3 | |
| SCHEMBL13056328 | 0.89 | HIF1AN (0.81) | MAP3K5PTPN22APEX1MAPTHIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | MAP3K5 2429/4885PTPN22 3261/4885APEX1 1513/4885 |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | APAF1, ANTXR2, SERPINB1 | MAP3K5 2429/4885PTPN22 3261/4885APEX1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.